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Combined Hyperl ip idemia Is Associated With Increased Exerc ise-Induced Muscle  
Protein Release Which Is Improved by Triglyceride-Lowering Intervent ion 
J.W.A. Smit,  T.W.A. De Bruin, E.M.W. Eekhoff, J. Glatz, and D.W. Erkelens 
Although myopathy is considered an adverse effect of treatment with 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) 
reductase inhibitors and fibrates in combined hyperlipidemia, the present study was performed to investigate whether 
combined hyperlipidemia itself is associated with skeletal muscle pathology and whether lipid-lowering intervention has 
beneficial effects. To investigate whether combined hyperlipidemia is associated with skeletal muscle pathology, 10 male 
patients and 15 normolipidemic controls underwent a 45-minute standardized bicycle ergometer test at a load of 2 W/kg lean 
body mass (parallel study). One- and 8-hour postexercise increments in the plasma level of the muscle proteins creatine kinase 
(CK), myoglobin (Mb), and fatty acid-binding protein (FABP) were assessed as parameters for (subclinical) skeletal muscle 
pathology. The 8-hour postexercise increments in CK and Mb and 1-hour postexercise increment in Mb were significantly 
higher in patients than in controls, thus indicating increased exercise-induced muscle membrane permeability in combined 
hyperlipidemia, To investigate the effects of lipid-lowering intervention on skeletal muscle in combined hyperlipidemia, 21 
subjects with combined hyperlipidemia were randomized double-blindly to receive 6 weeks of treatment with fluvastatin 40 
mg/d, gemfibrozil 600 mg twice daily, or combination therapy. All subjects underwent an ergometer test before and after 
treatment. GemfibrozU treatment alone reduced the CK increments 8 hours postexercise by 47% and the FABP increments 1 
and 8 hours postexercise by 83% and 101%, respectively (all P < .05). Combined treatment reduced Mb increments 1 hour 
postexercise by 54% and FABP increments 8 hours postexercise by 44% (all P < .05). A highly significant correlation existed 
between therapy-induced changes in plasma trigiycerides and changes in postexercise increments of FABP and Mb, In 
conclusion, combined hyperlipidemia is associated with an increased exercise-induced release of muscle proteins, which is 
ameliorated by triglyceride-lowering intervention. As FABP is an indicator for ischemia-induced skeletal muscle pathology, a 
possible explanation is the impaired muscle blood flow during hypertriglyceridemia, which may be reversed by triglyceride- 
lowering intervention. The mechanism and clinical relevance of these findings remain to be investigated. 
Copyright© 1999 by VV, B. Saunders Company 
W HILE THE RELATIONSHIP between elevated choles- terol levels and cardiovascular disease is beyond dis- 
pute, ~ controversy exists about the role of elevated triglyceride- 
rich lipoproteins in atherosclerosis. Recent studies have indicated 
a role of hypertriglyceridemia as a risk factor or risk indicator of 
cardiovascular disease. 2-4 As a consequence, triglyceride- 
carrying lipoproteins should be taken into account when 
considering lipid-lowering therapy in combined hyperlipid- 
emia. The treatment modalities in combined hyperlipidemia are 
nicotinic acid, inhibitors of 3-hydroxy-3-methylglutaryl- 
coenzyme A (HMG-CoA) reductase? and fibric acid deriva- 
tives, which decrease serum triglyceride levels by decreasing 
the synthesis of very-low-density lipoprotein cholesterol and 
increasing lipoprotein lipase activity. 6 Combination therapy 
with HMG-CoA reductase inhibitors plus fibrates is effective in 
the treatment of combined hyperlipidemia, which has been 
supported by several studies. 7-9 However, concern has arisen 
about myopathy and rhabdomyolysis during therapy with 
HMG-CoA reductase inhibitors combined with gemfibrozil.l°-15 
Moreover, gemfibrozil itself has also been associated with 
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myopathy. 16 Although a relationship with these medications 
seems apparent, elevated plasma muscle protein levels both at 
rest and after exercise have been observed in untreated familial 
hypercholesterolemia, as well, 17,18 leading to the conclusion that 
elevations of creatine kinase (CK) during therapy with HMG- 
CoA reductase inhibitors may not be caused by these agents 
alone. It has not been investigated whether combined hyperlip- 
idemia is also associated with increased serum levels of muscle 
proteins. This may be of importance, because elevated CK 
levels, which may be observed during therapy for combined 
hyperlipidemia, are usually attributed to this therapy and not to 
the disease. Moreover, it can be hypothesized that if combined 
hypeflipidemia is indeed associated with pathological serum 
muscle protein levels, lipid-lowering intervention may have 
beneficial effects. 
One of the explanations offered for the elevated muscle 
protein levels in familial hypercholesterolemia is impaired 
peripheral muscle blood flow, leading to diminished muscle 
blood flow. Indeed, it has been demonstrated that apart from 
coronary blood flOW, 19-21 peripheral blood flow is also impaired 
in hypercholesterolemia, which can be reversed by lipid- 
lowering therapy. 22-24 In hypertriglyceridemia, peripheral vascu- 
lar function is impaired as well, which also can be restored by 
lipid-lowering intervention. 25-27 
The exercise-induced release of the muscle proteins CK, 
myoglobin (Mb), and heart-type fatty acid-binding protein 
(FABP) 2s-32 is a well-established parameter for (sub)clinical 
muscular pathology. To assess whether combined hyperlipid- 
emia is associated with skeletal muscle pathology, the exercise- 
induced release of muscle proteins was compared in subjects 
with combined hypeflipidemia versus normolipidemic controls. 
To investigate whether therapy for combined hyperlipidemia 
has beneficial effects on skeletal muscle, a double-blind, 
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randomized ,  p lacebo-cont ro l led  in tervent ion s tudy was  per- 
formed.  In  this  study, the re lease  o f  musc l e  proteins  CK,  Mb,  
and  FABP after s tandardized exerc ise  was  a s se s sed  before  and 
after 6 weeks  o f  t rea tment  wi th  f luvastat in  and  gemfibrozi l ,  both  
as m o n o t h e r a p y  and  combined .  
SUBJECTS AND METHODS 
Intervention Study 
Informed consent was obtained from all patients. The study protocol 
was approved by the Medical Ethics Committee of the University 
Hospital Utrecht. In the intervention study, 21 patients with primary 
combined hyperlipidemia (10 men and 11 women aged 54 _+ 2 years, 
mean ± SE; body mass index [BMI], 26.6 _+ 0.5 kg/m 2) were selected 
among recently diagnosed hyperlipidemic patients from the Lipid 
Clinic of the University Hospital Utrecht. Patients with diabetes 
mellitus, renal, hepatic, muscle, or cardiac disease, or therapy with other 
medications known to be accompanied by myopathy or elevated muscle 
protein levels were excluded. Secondary causes for combined hyperlip- 
idemia were aiso excluded. Habitual physical exercise was scored as 
described previously ~8 using the following scale: 0, no exercise; 1, once 
per month but less than once per week; 2, at least once per week but of 
mild or moderate intensity (eg, sports for recreational purposes only); 
and 3, at least once per week but of high intensity (eg, sports 
competition or occupation involving heavy and frequent physical 
activity). The patients entered a dietary baseline period of 8 weeks. A 
standard lipid-lowering diet was prescribed by a dietician, containing 
50% of calories from carbohydrate, 20% from protein, and 30% from 
fat, with a polyunsaturated to saturated lipid ratio of 1. Daily intake of 
cholesterol was less than 300 mg. At the end of the 8-week baseline 
period, patients with low-density lipoprotein (LDL) cholesterol of at 
least 4.14 mmol/L and fasting triglycerides of at least 2.3 mmol/L were 
randomized in a double-blind manner to be treated for 6 weeks with 
either fluvastatin 40 mg/d taken at bedtime and gemfibrozil placebo 
(fluvastatin group, n = 7), gemfibrozil 600 mg twice daily and fluva- 
statin placebo (gemfibrozil group, n = 7), or a combination of fluva- 
statin 40 mg/d and gemfibrozi1600 mg twice daily (combined treatment 
group, n = 7). The placebo tablets contained lactose and resembled the 
fluvastatin or gemfibrozil tablets. In the last week of the dietary baseline 
period and after 6 weeks of active treatment, an exercise provocation 
test was performed. 
Comparison of Subjects With Combined Hyperlipidemia 
Versus Normolipidemic Controls 
To investigate whether combined hyperlipidemia is associated with a 
pathological exercise-induced release of muscle proteins, the results 
from a subgroup of 10 male patients with primary combined hyperlipid- 
emia from the intervention study (age, 43 _+ 2 years; BMI, 26.1 ± 0.6 
kg/m 2) were compared with those of an age-, BMI-, and habitual 
exercise-matched normolipidemic control group consisting of 15 healthy 
males (age, 48 2 2; BMI, 25.8 _+ 0.8) recruited from laboratory person- 
nel and used previously to assess whether primary hypercholesterol- 
emia is associated with increased exercise-induced release of muscle 
proteins? 2 Controls were screened for conditions known to influence 
muscle protein release. Since they were normolipidemic, subjects in the 
control group were not prescribed a diet. 
Ergometer Test 
The bicycle ergometer test was used previously to detect subjects 
with muscular disease and to study exercise-induced skeletal muscle 
protein release in hypercholesterolemia, and is described in detail 
elsewhere. 22 In short, a 45-minute bicycle ergometer test was performed 
with a load of 2 W/kg lean body mass. The actual workload was 
registered every 5 minutes. In the intervention study, the workload 
during the second exercise test (in the last week of the active treatment 
period) was kept identical to the workload during the first test at any 
time point for each individual. Female participants performed the 
second exercise test in the same phase of the menstrual cycle as the first 
test. The patients were told to avoid strenuous exercise for 48 hours 
before both tests. Blood samples for CK, Mb, and FABP analysis were 
taken before the exercise test and 1 and 8 hours after the test. It was 
demonstrated that peak CK levels occur 8 hours after this test.18,28 
Peak Mb levels are observed 1 hour after exercise and the same is 
expected for FABP, as FABP and Mb plasma levels are usually strongly 
correlated. 3°32 Exercise-induced muscle damage is reflected by an 
increment in muscle protein levels after exercise. In the normolipidemic 
control group, only CK and Mb levels were assessed, and therefore, no 
comparison with the hyperlipidemic patients for exercise-induced 
FABP levels could be performed. 
Laboratory Methods 
Total cholesterol, triglycerides, and CK were determined by enzy- 
matic-colorimetric methods (CHOD-PAP and GPO-PAP; Boehringer, 
Mannheim, Germany). High-density lipoprotein (HDL) cholesterol was 
determined in the supematant after precipitation of apolipoprotein 
B-containing lipoproteins. LDL cholesterol was calculated using the 
Friedewald formula, since fasting triglycerides were less than 5.6 
mmol/L in all subjects on all occasions. 33 Mb was determined using the 
Bebring Latex Myoglobin Kit (Behring Diagnostics, Frankfurt, Ger- 
many). Heart-type FABP was determined in plasma using an enzyme- 
linked immunosorbent assay of the antigen-capture type (sandwich 
ELISA). This method has been described in detail elsewhere. 3° Samples 
from each subject were measured in duplicate in the same assay, using 
the average of both values. 
Safety Parameters 
The laboratory safety parameters were plasma creatinine, sodium, 
potassium, bilirubin, alanine aminotransferase, aspartate aminotransfer- 
ase, and gamma-glutamyl transferase, a hematological profile, and a 
urinary analysis. A physical examination and measurement of the blood 
pressure and pulse were performed at each visit during the intervention 
study. A 12-lead electrocardiogram was performed at the beginning of 
the baseline period. 
Statistical Methods 
All values are presented as the mean -+ SE. In the intervention study, 
lipid parameters and preexercise CK, Mb, and FABP levels before and 
after treatment within each group were analyzed with a two-sided, 
paired Student's Ttest. The exercise-induced elevations of CK, Mb, and 
FABP were analyzed within each group using a paired Wilcoxon test. 
Data from patients and normolipidemic controls were compared using 
an unpaired T test for age, BMI, lipids, and baseline CK and Mb. 
Exercise-induced levels of muscle proteins between the two groups 
were compared with an unpaired Wilcoxon test. Correlations between 
lipid levels and exercise-induced muscle protein increments were 
calculated with linear regression. A P value tess than .05 was considered 
statistically significant. 
RESULTS 
Comparison of Subjects With Combined Hyperlipidemia and 
Normolipidemic Controls 
Patients. In the parallel  study, both groups  were  identical  
with  regard  to age, BMI,  and habi tual  exerc ise  (Table 1). 
Ergometer test. The  exerc i se - induced  C K  increase  after 1 
hour  was the same,  but  at 8 hours  after exercise,  it was  
s ignif icant ly h igher  in pat ients  with combined  hyper l ip idemia  
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Table 1. Comparison of Subjects With Combined Hyperlipidemia 
and Normolipidemic Controls 
Characteristic Patients Controls 
No. of subjects 10 15 
Age (yr) 43.3 + 2.2 48 ± 1.7 
BMI (kg/m 2) 26.1 ± 0.6 25.8 ± 0.8 
Exercise score 1.7 +_ 0.2 1,4 ± 0.6 
LDL cholesterol (retool/L) 5.7 _+ 0.5 3.7 +_ 0.3 
HDL cholesterol (retool/L) 0.9 +_ 0.05 1.1 ± 0.1 
Triglycerides (mmol/L) 4.2 _+ 0.5 1.2 ± 0,1 
NOTE. Values are the mean ± SD. 
than in normocholesterolemic controls (39.1 + 6.9 v 9.7 + 3.3 
U/L, P = .0002; Fig 1). The increase in Mb differed signifi- 
cantly between patients and controls both 1 hour after exercise 
(17.7 + 4.2 ng/L for patients v 4.1 + 2.8 ng/L for controls, 
P = .006) and 8 hours after exercise (9.2 + 2.4 v -5 .9  ~ 2.2 
ng/L, P = .0003). 
Intervention Study 
Patients. Characteristics of the three treatment groups are 
listed in Table 2. No clinical adverse effects occurred during the 
study period or thereafter. One patient from the gemfibrozil 
group left the study because he found the procedures too 
burdensome. This patient was not included in any analysis. 
Lipid parameters. Plasma lipid concentrations are pre- 
sented in Table 3. The combined treatment group showed the 
highest reductions in LDL cholesterol and triglycerides, which 
were significantly decreased by 29% and 49%, respectively. 
Ergometer test. Each subject had an identical workload at 
any time point during both exercise tests. Preexercise plasma 
CK, Mb, and FABP and exercise-induced increments are shown 
in Table 4. Preexercise plasma muscle protein levels did not 
differ between the baseline exercise test and the second exercise 
test in all three treatment groups. The plasma ratio Mb/FABP 
was more than 10 in all groups before and after both exercise 
tests (data not shown), which is in line with skeletal muscle as a 
source of these proteins.3°-32 After gemfibrozil treatment, postex- 
ercise increments of CK (8 hours postexercise) and FABP (1 
and 8 hours postexercise) were significantly lower versus before 
therapy. In addition, after combination therapy, the 1-hour 
postexercise increment of Mb and the 8-hour postexercise 
increment of FABP were significantly lower versus before 
treatment. 
50 
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Table 2. Patient Characteristics in the Intervention Study 
(mean -+ SD) 
Characteristic Fluvastatin Gernfibrozil Combination 
Sex ratio (male/female) 3/4 3/3 3/4 
Age (yr) 56 ± 8 50 ± 4 56 ± 2 
Weight (kg) 77.6 _+ 2.9 78.4 -- 4,9 80.3 ± 2.6 
BMI (kg/m 2) 27.3 _+ 0.7 25.4 ± 0.4 26.9 + 0.5 
Correlation between lipid parameters and muscle proteins. 
No correlation was found between absolute plasma lipid levels 
(before or after treatment) and exercise-induced increments of 
muscle proteins. However, in the intervention study, significant 
correlations existed between therapy-induced changes in plasma 
triglyceride levels and changes in Mb increments (1 hour after 
exercise, r = .54, P =  .016; 8 hours after exercise, r = .68, 
P = .00i) and FABP increments 1 hour after exercise (r = .62, 
P = .016; Fig 1). A striking finding was that in 19 of 20 subjects 
who completed the intervention study, the direction (increase or 
decrease) of the therapy-induced change in triglycerides paral- 
leled the direction of change in the 1-hour postexercise FABP 
increment (Fig 2). No correlations were observed between 
therapy-induced changes in total cholesterol, LDL cholesterol, 
or HDL cholesterol and changes in exercise-induced increments 
in muscle proteins. 
DISCUSSION 
The present study was performed to assess whether combined 
hyperlipidemia is associated with increased exercise-induced 
release of muscle proteins and whether lipid-lowering interven- 
tion has beneficial effects. 
We found an indication for increased exercise-induced re- 
lease of muscle proteins in subjects with combined hyperlipid- 
emia compared with normolipidemic controls. Although the 
comparison of results between patients and controls should be 
performed carefully since it cannot be excluded that unknown 
selection factors may have played a role, special care was taken 
to exclude the influence of conditions that are known to affect 
exercise-induced muscle protein release, In the intervention 
study in both the gemfibrozil treatment group and the combina- 
tion therapy group, the exercise-induced increments of muscle 
proteins were smaller as compared with pretreatment values. 
Although, theoretically, the decreased increments may result 
from decreased release or increased clearance of muscle 
IH  8H 
Hours After Exercise 
Fig 1. Exercise-induced incre- 
ments in plasma CK and Mb after 
standardized exercise in 10 male 
subjects with combined hyperlip- 
idemia ( [ ] )  and 15 normolipid- 
emic male controls (BB). In- 
creases in CK 8 hours after 
exercise and Mb 1 and 8 hours 
after exercise differed signifi- 
cantly between patients and con- 
trois. *P = .0002, #P = .006, .P = 
.0003. 
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Table 3. Lipid Profile (mmol/L) in 20 Subjects With Combined 
Hyperlipidemia Before and After 6 Weeks of Treatment With 
Fluvastatin 40 mg/d, Gemfibrozil 600 mg Twice Daily, or a 
Combination of Both (Intervention Study) 
Fluvastatin Gemfibrozil Combination 











8.4 ± 0,4 9.0 ± 0.8 8.3 ± 0.4 
5.4 ± 0.4 6.3 +- 0.7 5.5 ± 0.4 
1.1 + 0,1 1.1 ± 0.1 1.2 -+ 0.1 
4.3 -+ 0.7 3.9 ± 0.4 3.5 ± 0.7 
6 . 5 ± 0 . 4 "  - 2 3  7 .8 -+0 .5  - 1 3  6.0+-0,5§ - 2 8  
3 . 4 ± 0 . 3 t  - 3 7  5.4_+0.5 - 1 4  3.9±0.91[ - 2 9  
1 . 1 ± 0 . 1  0 1 . 3 ± & 5  +18 1.3-+0.1 +8  
4 . 4 ±  1.1 +2  2.4_+0.35 - 3 8  1 . 8 ± 0 . 3 ¶  - 4 9  
Abbreviat ions:  LDLC, LDL cholesterol;  HDLC, HDL cholesterol;  TG, 
tr iglycerides. 
*P  = .009, I-P = .003, ~:P = .006, §P = .034, liP = .012, ¶P = .036: v 
corresponding basel ine value. 
proteins, the latter seems unlikely since it is known from the 
literature that neither lipid-lowering drugs as applied in this 
study nor hyperlipidemia itself affect kidney function in other- 
wise healthy patients. In addition, creatinine levels in the patient 
groups remained unchanged throughout the study. In one 
study, 17 hypercholesterolemia was associated with increased 
serum CK-MM and not CK-MBs, which makes an effect of 
hyperlipidemia on CK clearance unlikely. The decrease in the 
postexercise FABP increment during gemfibrozil was remark- 
able, since this agent is known to induce peroxisomes and hence 
to increase intracellular FABP levels. 34 If gemfibrozil therapy 
influenced plasma FABP levels directly, elevated rather than 
reduced FABP increments would be expected. Analysis of the 
therapy-induced changes in plasma lipid levels and postexercise 
muscle protein increments showed a highly significant correla- 
tion between improved plasma triglycerides and postexercise 
Mb and FABP increments. The correlation between these 
parameters was even stronger when the direction of the change 
(positive or negative) was considered: in all but one subject, the 
direction of the change in triglycerides paralleled the direction 
of change in the 1-hour postexercise FABP increment. In 
contrast, no correlation was found between changes in total or 
LDL cholesterol and changes in muscle proteins. This is in line 
with the observation that in the groups with the greatest 
reduction in triglycerides, ie, the gemfibrozil and combined 
treatment groups, favorable effects on postexercise increments 
of muscle proteins were found. 
These results suggest that combined hyperlipidemia is associ- 
ated with increased exercise-induced release of muscle proteins 
and that reducing triglyceride levels has a beneficial effect. As 
an explanation, it may be suggested that changes in triglyceride- 
carrying lipoproteins affect muscle membrane stability directly, 
explaining the reduced leakage of muscle proteins after exer- 
cise. This seems unlikely, because cholesterol and phospholipid 
composition determine cellular membrane stability, rather than 
plasma triglyceride and fatty acid concentrations. Moreover, the 
literature suggests a decrease in membrane stability associated 
with decreased lipid levels. 35 A direct beneficial effect of the 
pharmaceutical compounds on muscle is even more unlikely, as 
both HMG-CoA reductase inhibitors and fibrates have been 
associated with myopathy. 1°-15 As another explanation, it may 
be hypothesized that triglyceride-lowering intervennon may 
affect the metabolism of carbohydrates or fatty acids in skeletal 
muscle, thereby influencing the exercise endurance. However, 
no such effects were found in a study with gemfibrozil in 
humans 36 or a study with peroxisomal proliferators in rats. 37 A 
more suitable explanation for the Observed reduction in the 
exercise-induced increment of muscle proteins is an improve- 
ment in muscle blood flow and, consequently, blood supply to 
skeletal muscle during triglyceride-lowering therapy. Improved 
peripheral vascular function has been demonstrated in hypertri- 
glyceridemic subjects treated with fibrates. 25 Although we did 
not measure muscle blood flow directly, it has been demon- 
strated that ~lasma FABP is a sensitive parameter for ischemia- 
induced muscular damage. 30-32 Therefore, we believe improved 
muscle blood flow is a possible explanation for the beneficial 
effects on FABP and Mb release observed during triglyceride 
reduction. However, the exact mechanism of the relation 
between triglyceride and exercise-induced muscle protein lev- 
Table 4. Influence of Standardized Exercise on Plasma Levels of CK, 
Mb, and FABP in 20 Subjects With Combined Hyperlipidemia Before 
and After 6 Weeks of Treatment With Fluvastatin 40 mg/d, 
Gemfibrozi1600 mg Twice Daily, or a Combination of Both 
(Intervention Study) 
Fluvastatin Gemfibrozil Combination 
Parameter (n = 7) (n = 6) (n = 7) 
CK (U/L) 
First exercise test 
Preexercise 
A t =  1 h 




A t = l h  
A t = 8 h  
Mb (Mg/L) 
First exercise test 
Preexercise 
A t = l h  




A t = l h  
A t = 8 h  
FABP (#g/L) 
First exercise test 
Preexerclse 
A t = l h  




A t = l h  
A t = 8 h  
71.9 -+ 7.6 74.5 -+ 7.1 52.9 ~ 4.3 
4.0 +_ 2.2 2.7 -+ 1.0 2.9 ± 1.5 
41.0 ± 12.0 43.3 ± 13.8 31.9 -+ 8.2 
71.6 + 7.3 73.3 ± 11.0 45.1 ± 14.6 
5.1 _+ 1.9 3.5 ± 3.0 8.0 -- 2.5 
46.3 ± 19.6 23.0 ± 6.9* 52,9 ± 24.8 
30.1 + 4.1 30.5 ± 3,3 23.2 ± 3.0 
17.0 _+ 5.9 15.5 _+ 4,7 12.3 ± 9.2 
5,1 -+ 6,9 9~5 -+ 4.7 7.29 + 10.0 
31.7 ± 2.9 30.5 ± 2.4 30.4 + 7.3 
20.69 ± 8.6 11.7 ± 4.1 5.7 -+ 3.1t 
13.3 ± 6.3 3.8 ± 3.9 - 8 . 9  ± 15.9 
2.46 ± 0.57 2.44 _+ 0.65 2.16 ± 0.71 
0.78 ± 0.61 1.20 ± 0.93 0.81 ± 0.81 
0.73 ± 0,82 0.92 ± 0.86 0.27 ± 0.68 
2.73 ± 1.02 2.96 _+ 0.52 2.29 -+ 0.90 
1.55 ± 1,16 0.21 ± 0.55* 1.02 _+ 1.43 
0,53 -- 0.52 -0.01 ± 0.651- 0.15 -+ 1.325 
NOTE. First exercise test, before any t reatment;  second exercise 
test, after 6 weeks of  t reatment.  For At = 1 h, data on plasma CK levels 
are calculated as fe l lows:  1 h postexercise minus preexercise CK level. 
*P  = ,028, t P  = .043, SP = .046: v f i r s t  exercise test. 
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Fig 2. Correlations between 
changes (A) in plasma triglycer- 
ides or LDL cholesterol and 
changes in exercise-induced in- 
crements of plasma muscle pro- 
teins (FABP 1 hour postexercise 
and Mb 8 hours postexercise) in 
20 subjects with combined hy- 
perlipidemia. The data reflect 
changes v baseline (before 
therapy) after 6 weeks of treat- 
ment with fluvastatin 40 mg/d, 
gemfibrozil 600 mg twice daily, 
or a combination of both. A, 
baseline value minus value after 
therapy. 
els remains to be elucidated. In addition, the question remains as 
to why changes in LDL cholesterol levels with fluvastatin 
appeared not to contribute to the improved postexercise muscle 
protein release. In this study, we found evidence for skeletal 
muscle pathology in untreated hypertriglyceridemia. As a 
consequence, the elevated muscle protein levels observed 
directly after starting therapy for combined hyperlipidemia may 
result from the disease rather than the therapy. However, we still 
advise monitoring patients on combination therapy for adverse 
effects. It appears from the literature that myopathy during 
therapy with HMG-CoA reductase inhibitors is associated with 
elevated systemic levels of these agents, which can occur in the 
case of hepatic or, multiple-organ failure or during concomitant 
therapy with agents that interfere with the hepatic clearance of 
HMG-CoA reductase inhibitors (eg, cyclosporin)? s The mecha- 
nism of muscle toxicity by statins may be a direct toxic effect 39 
or perhaps represents a yet unknown interaction with a genetic 
muscle Susceptibility. Gemfibrozil may induce myopathy, espe- 
cially when renal function is impaired. 
In conclusion, in this study, evidence has been found that 
combined hyperlipidemia is associated with increased release of 
muscle proteins after exercise and that decreasing triglyceride- 
carrying lipoproteins ameliorates the exercise endurance of 
skeletal muscle. The clinical significance of these observations 
remains to be proven. The decision on which therapy to use in 
the prevention of coronary heart disease should be based 
primarily on efficacy with regard to clinical relevant endpoints. 
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